SYNLAB and NHS create diagnostic partnership

SYNLAB has commenced a 15-year partnership with the UK’s NHS to deliver and transform medical diagnostic services for more than two million people as part of one of the largest medical diagnostic partnerships in Europe.

In the scope of the partnership, SYNLAB will transform services by implementing a ‘hub and spoke’ pathology model. This includes building state-of-the-art laboratories and implementing cutting edge IT systems, directly linking laboratories with referral sites.

Read more: Sensyne Health gets approval for AI Covid test algorithm

This will not just enable faster testing services but will also significantly improve access to a comprehensive offering of medical diagnostic services.

The new hub laboratory will become home to a fully-equipped training centre dedicated to excellence in medical diagnostics, offering learning and development opportunities to scientists, NHS clinicians, junior doctors and others working across all healthcare settings.

Mathieu Floreani, Chief Executive Officer for SYNLAB Group, emphasises the added value for patients: “This partnership is built on a passion for medical excellence and customer-centricity, meaning that our patients and medical customers are always at the heart of our work. Together with our partners, we will provide people and patients in South East London and beyond with digitally innovative, faster medical diagnostic services which add great value to the NHS.”

SYNLAB Group is the largest European clinical laboratory and medical diagnostic services provider by revenue and number of tests. SYNLAB offers a full range of innovative and reliable medical diagnostics for patients, practising doctors, clinics and the pharmaceutical industry.

The Group operates in 36 countries across four continents and holds leading positions in most markets, and employs 20,000 employees including over 1,200 medical experts, as well as a large number of other specialists such as biologists, chemists and laboratory technicians. SYNLAB carries out approximately 500 million laboratory tests per year and achieved Group revenues of €2.6 billion in 2020.

Read more: AI glove to improve hand grip for millions with muscle weakness

In April, the Group announced a planned initial public offering (IPO), subject to the approval of the prospectus by the German Federal Financial Supervisory Authority and its publication.

SYNLAB aims to raise gross proceeds of approximately €400 million from the sale of the newly created shares placed in the offering. The Group intends to use the proceeds to repay parts of its outstanding debt obligations, resulting in a further reduction of leverage.

Back to Homepage

Back to Healthcare